Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

• المؤلفون الرئيسيون: Ou, S.-H.I, Soo, R.A, Kubo, A, Kawaguchi, T, Ahn, M.-J
• مؤلفون آخرون: CANCER SCIENCE INSTITUTE OF SINGAPORE
• التنسيق: Review
• منشور في: 2020
• الموضوعات: anaplastic lymphoma kinase; brain derived neurotrophic factor receptor; cabozantinib; CD74 antigen; crizotinib; lenvatinib; platelet derived growth factor alpha receptor; platelet derived growth factor receptor; ponatinib; protein Ret; protein tyrosine kinase; protein tyrosine kinase A; protein tyrosine kinase inhibitor; Raf protein; regorafenib; sorafenib; sunitinib; vandetanib; vasculotropin receptor 1; vasculotropin receptor 3; breast cancer; chronic myelomonocytic leukemia; clinical trial (topic); colorectal carcinoma; cost effectiveness analysis; DNA transfection; drug approval; drug industry; fluorescence in situ hybridization; food and drug administration; gene rearrangement; human; immunohistochemistry; lung non small cell cancer; molecular diagnostics; off label drug use; reverse transcription polymerase chain reaction; review; sequence analysis; sequence homology; thyroid cancer
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/183179

10.3389/fonc.2014.00058